Feb 19 2013, 5:26am CST | by Luigi Lugmayr
Washington, Feb 19 — Hepatitis C virus (HCV) infection affects about 4.1 million people in the United States alone and is the primary cause of liver cirrhosis and liver cancer. Current therapy against the infection is not particularly effective.
An interdisciplinary effort by mathematical modellers, clinicians and molecular virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a new, more accurate estimate of the HCV half-life, the journal Proceedings of the National Academy of Sciences reports.
"Ultimately, our study will help design better DAA drug cocktails to treat HCV," said Loyola University Health System (LUHS) and Stritch School of Medicine (SSOM) mathematical modeller Harel Dahari, who co-led the study.
Dahari is one of five members of the Division of Hepatology at Loyola headed by Scott Cotler, who authored the study with Thomas Layden, HCV virologist Susan L. Uprichard and her doctoral graduate student Natasha Sansone, according to a Loyola statement.
"Daclatasvir not only blocks the synthesis of the viral RNA within infected cells but also secretion of infectious virus from the cells," said Dahari.
This prediction was confirmed in Uprichard's lab using cultured liver cells that support the entire life cycle of HCV infection.
Luigi is the founding Chief Editor of I4U News and brings over 15 years experience in the technology field to the ever evolving and exciting world of gadgets. He started I4U News back in 2000 and evolved it into vibrant technology magazine.
Luigi can be contacted directly at email@example.com. Luigi posts regularly on LuigiMe.com about his experience running I4U.
blog comments powered by Disqus